What Happens to a Child’s Height After a Stem Cell Transplant? Researchers Find an Encouraging Answer

HIROSHIMA, Japan — Growth hormone therapy significantly improves adult height outcomes for children who experience severe growth impairment following hematopoietic stem cell transplantation (HCT), according to a study published on May 20, 2026.

The nationwide investigation, conducted by researchers at Hiroshima University and the Japanese Children's Cancer Group, highlights a critical development for pediatric cancer survivors. While stem cell transplants serve as life-saving interventions for malignant and non-malignant childhood conditions, post-transplant short stature remains a prevalent late effect. The newly published findings confirm that therapeutic intervention with growth hormone offers long-term benefits, though the extent of growth depends heavily on prior cancer treatments and transplant-related medical complications.

Nationwide Study Reveals Sustained Growth Benefits

Researchers conducted a nationwide, multicenter retrospective cohort study evaluating childhood stem cell transplant survivors diagnosed with post-transplant short stature. The trial tracked 268 patients across Japan, analyzing long-term height outcomes measured through final adult height standard deviation scores (SDS). Out of 171 patients with completed final height data, 58 received growth hormone therapy while 113 did not.

Statistical analysis demonstrated that patients receiving growth hormone therapy achieved significantly improved final adult height compared to those untreated. Crucially, researchers observed that height gains often continued for several years following the initiation of treatment, with progress persisting up to five years and through final adult height. This sustained growth trajectory differs noticeably from patterns observed in patients treated for classical growth hormone deficiency.

Impact of Radiation and Transplant Complications

Despite positive general outcomes, the study identified key clinical variables that limit treatment effectiveness. Total body irradiation (TBI)—a standard radiotherapy protocol used prior to transplantation to suppress recipient immune systems and eliminate cancer cells—was identified as the strongest negative predictor of height outcome.

Furthermore, clinical responses varied depending on transplant type and post-procedure health:

• Transplant Type: Outcome variations emerged between autologous transplants (using the patient's own stem cells) and allogeneic transplants (using donor stem cells).

• Graft-Versus-Host Disease: Patients suffering from chronic graft-versus-host disease (GVHD) experienced reduced growth responsiveness.

• Biological Mechanisms: Distinct biological pathways underlying post-transplant growth failure require ongoing, individualized management strategies.

Official Statements

According to official research disclosures published in Frontiers in Endocrinology, growth outcomes remain tied to specific conditioning regimens administered before stem cell infusion.

"Growth impairment is one of the most common long-term complications in children who undergo HCT," stated Maiko Shimomura, assistant professor at Hiroshima University Hospital and lead author of the study. "We aimed to determine whether GH therapy improves final height outcomes in childhood HCT survivors and to identify clinical factors associated with treatment response. This is important because the number of childhood transplant survivors is increasing, and improving long-term health and quality of life has become a major goal of survivorship care."

"GH therapy was associated with improved final height outcomes in childhood HCT survivors with short statures," Shimomura added. "However, treatment responses were highly variable. Growth outcomes were strongly influenced by transplant-related factors such as total body irradiation and chronic graft-versus-host disease. Our findings suggest that GH therapy is beneficial, but individualized long-term management is essential."

Why It Matters

As survival rates for pediatric cancers and severe blood disorders continue to rise due to advancements in transplant medicine, focus has shifted toward long-term survivorship care. Short stature can affect a survivor's psychological well-being and overall quality of life. Demonstrating that growth hormone therapy provides multi-year height gains helps clinical endocrinologists design targeted, post-transplant care protocols tailored to individual risk factors.

Key Facts at a Glance

• Target Population: Childhood survivors of hematopoietic stem cell transplantation (HCT) experiencing growth impairment.

• Primary Finding: Growth hormone therapy improves final adult height SDS, with benefits continuing up to 5 years post-treatment.

• Major Inhibiting Factors: Prior total body irradiation (TBI) and chronic graft-versus-host disease (GVHD) significantly reduce height response.

• Research Leadership: Led by Hiroshima University and the Japanese Children's Cancer Group.

Frequently Asked Questions

What causes growth failure in children after stem cell transplants?

Growth impairment typically results from high-dose chemotherapy, total body irradiation affecting the pituitary gland and bone growth plates, and complications like chronic graft-versus-host disease.

How does growth hormone therapy differ for transplant survivors compared to other patients?

Unlike patients with classical growth hormone deficiency who often see growth velocity plateau early, transplant survivors on growth hormone therapy often show continuous height improvements spanning five or more years.

Does total body irradiation prevent growth hormone therapy from working?